TILLOTTS PHARMA LIMITED

Tillotts Pharma Limited is a specialist Irish pharmaceutical company dedicated to improving the lives of people living with gastrointestinal (GI) diseases. Their core mission is to advance care for patients with inflammatory bowel disease—including ulcerative colitis, Crohn’s disease and microscopic colitis—as well as those affected by *Clostridioides difficile* infection. By developing and supplying targeted therapies such as Octasa, Entocort Enema and budesonide CR 3 mg capsules, Tillotts supports both Ireland’s healthcare professionals and resident patients in managing symptoms, maintaining remission and reducing the risk of serious complications.

The company’s expertise extends across the full spectrum of GI health, from education on disease mechanisms to the provision of evidence‑based treatments. Their team of dedicated scientists, clinicians and support staff work collaboratively to ensure that the latest advances reach the bedside quickly and safely. With a clear focus on patient‑centred care, Tillotts Pharma stands as a trusted partner in the Irish healthcare landscape, championing better outcomes for those affected by gut‑related conditions.